Joint with: Stem Cells and Regeneration
Emerging Cellular Therapies
January 22-25, 2024 | Santa Fe Community Convention Center, Santa Fe, NM, United States
Scientific Organizers:
Dan S. Kaufman, Kiem and Sonja Schrepfer
In Person
On Demand
January 22-25, 2024 | Santa Fe Community Convention Center, Santa Fe, NM, United States
Scientific Organizers:
Dan S. Kaufman, Kiem and Sonja Schrepfer
Available Formats:
In Person
On Demand
Supported by the Directors' Fund
Available Formats: = In Person = On Demand
Merchandise Options
Registration Options
Booking Function
Fundraising
Monday, January 22, 2024
Arrival and Registration
4:00–8:00 PM
Sweeney Ballroom Foyer
Welcome Mixer
6:00–8:00 PM
Sweeney Ballroom Foyer
Tuesday, January 23, 2024
Breakfast
7:00–8:00 AM
Sweeney Ballroom F
Poster Setup
7:30–8:00 AM
Sweeney Ballroom F
Poster Viewing
8:00–7:00 PM
Sweeney Ballroom F
Welcome and Keynote Session (Joint)
8:00–9:30 AM
Sweeney Ballroom A-B
Drew Weissman, University of Pennsylvania
In vivo LNP-mRNA Therapies
In vivo LNP-mRNA Therapies
Juan Carlos Izpisua-Belmonte, Altos Labs
in vivo Reprogramming for Rejuvenation
in vivo Reprogramming for Rejuvenation
Coffee Break
9:30–9:50 AM
Sweeney Ballroom Foyer
Cell Engineering and Regenerative Therapies (Joint)
9:50–11:15 AM
Sweeney Ballroom A-B
Yvonne Y. Chen, University of California, Los Angeles
Programming Novel Cancer Therapeutics
Programming Novel Cancer Therapeutics
Masayo Takahashi, RIKEN Center for Developmental Biology
Cell and Gene Therapy for Retinal Regeneration
Cell and Gene Therapy for Retinal Regeneration
Vardhman Kumar, MIT
Short Talk: Injectable and Modular Multicellular Liver Tissue Engineering
Short Talk: Injectable and Modular Multicellular Liver Tissue Engineering
Irene Lorenzo Llorente, Stanford University
Short Talk: Allogeneic Regenerative Cell Therapy for White Matter Stroke and Vascular Dementia
Short Talk: Allogeneic Regenerative Cell Therapy for White Matter Stroke and Vascular Dementia
Lunch
11:30–12:30 PM
Sweeney Ballroom F
Poster Session 1
12:00–2:30 PM
Sweeney Ballroom F
Career Roundtable (Joint)
3:00–4:30 PM
Samik Basu, Cabaletta Bio
Chief Scientific Officer
Chief Scientific Officer
Maria Pia E. Cosma, Centre for Genomic Regulation
ICREA Research Professor and Senior Scientist
ICREA Research Professor and Senior Scientist
Katy Rezvani, University of Texas MD Anderson Cancer Center
Professor
Professor
Quinton Smith, University of California, Irvine
Assistant Professor
Assistant Professor
Coffee Available
4:30–5:00 PM
Sweeney Ballroom Foyer
Strategies for Engineered Cell Therapies
5:00–7:00 PM
Sweeney Ballroom A-B
Jonathan Yen, St. Jude Children's Research Hospital
Therapeutic Genome Editing of Hematopoietic Stem Cells for the Treatment of Sickle Cell Disease
Therapeutic Genome Editing of Hematopoietic Stem Cells for the Treatment of Sickle Cell Disease
Paula M. Cannon, University of Southern California, Keck School of Medicine
Genome Edited B Cells for Custom Antibody Production
Genome Edited B Cells for Custom Antibody Production
Hans-Peter Kiem, Fred Hutchinson Cancer Center
New Approaches for Cell Therapy Against Malignant and Infectious Disease
New Approaches for Cell Therapy Against Malignant and Infectious Disease
Robert Mabry, Orna Therapeutics
Short Talk: ORN-101 isCAR Therapy for the Treatment of B Cell Malignancies
Short Talk: ORN-101 isCAR Therapy for the Treatment of B Cell Malignancies
Hanlan Liu, Be Bio
Short Talk: Development of an Ex Vivo Precision Gene Engineered B Cell Medicine Platform that Produces Active and Sustained Levels of Therapeutic Proteins with Broad Utility in Rare Diseases and Cancer
Short Talk: Development of an Ex Vivo Precision Gene Engineered B Cell Medicine Platform that Produces Active and Sustained Levels of Therapeutic Proteins with Broad Utility in Rare Diseases and Cancer
On Own for Dinner
7:00–8:00 PM
Wednesday, January 24, 2024
Breakfast
7:00–8:00 AM
Sweeney Ballroom F
iPSC-Derived Therapies for Non-Malignant Disease
8:00–11:00 AM
Sweeney Ballroom A-B
Sonja Schrepfer, University of California, San Francisco and Sana Biotechnology
Production of Immune Privileged iPSCs
Production of Immune Privileged iPSCs
Lorenz Studer, Memorial Sloan Kettering Cancer Center
iPSC-Derived Treatment for Parkinson's Disease
iPSC-Derived Treatment for Parkinson's Disease
Steven Havlicek, Neurona Therapeutics
NRTX-1001 - A Human Pluripotent Stem Cell-Derived Inhibitory Interneuron Cell Therapy For Drug-Refractory Focal Epilepsy: From Preclinical Characterization To First Clinical Trial Results
NRTX-1001 - A Human Pluripotent Stem Cell-Derived Inhibitory Interneuron Cell Therapy For Drug-Refractory Focal Epilepsy: From Preclinical Characterization To First Clinical Trial Results
Christine L. Mummery, Leiden University Medical Center
Discovering Therapies for the CVD using hiPSC
Discovering Therapies for the CVD using hiPSC
Hans-Willem E. Snoeck, Columbia University Medical Center
Short Talk: Engraftment and Injury Repair in Regionally Conditioned Rat Lung in vivo by Lung Progenitors Derived from Human Pluripotent Stem Cells
Short Talk: Engraftment and Injury Repair in Regionally Conditioned Rat Lung in vivo by Lung Progenitors Derived from Human Pluripotent Stem Cells
Sophia Silver, Clemson University
Short Talk: Nanowired Human Cardiac Organoid Transplantation Enables Highly Efficient and Effective Recovery of Infarcted Hearts
Short Talk: Nanowired Human Cardiac Organoid Transplantation Enables Highly Efficient and Effective Recovery of Infarcted Hearts
Coffee Break
9:00–9:20 AM
Sweeney Ballroom Foyer
On Own for Lunch
11:00–5:00 PM
Poster Setup
11:00–1:00 PM
Sweeney Ballroom F
Poster Viewing
1:00–10:00 PM
Sweeney Ballroom F
Workshop: Advances in Cell Therapies
2:30–4:30 PM
Sweeney Ballroom A-B
Tina Tylek, Drexel University
Biomaterial-enabled Macrophage Cell Therapy for Regenerative Medicine
Biomaterial-enabled Macrophage Cell Therapy for Regenerative Medicine
Sandra Petrus-Reurer, University of Cambridge
Generation and Characterization of ‘Universal’ Low-Immunogenic Human Primary Cholangiocyte Organoids for Treatment of Bile Duct Disorders
Generation and Characterization of ‘Universal’ Low-Immunogenic Human Primary Cholangiocyte Organoids for Treatment of Bile Duct Disorders
Nicholas Kalogriopoulos, Stanford University
Programmable Synthetic GPCRs for Customized Antigen-dependent Control of Cell Behaviors
Programmable Synthetic GPCRs for Customized Antigen-dependent Control of Cell Behaviors
May Daher, MD Anderson Cancer Center
Myeloid Blasts Induce an Irreversible Epigenetic Scar in NK Cells Leading to a Global Dysfunction
Myeloid Blasts Induce an Irreversible Epigenetic Scar in NK Cells Leading to a Global Dysfunction
Christopher Chang, UCSF
One-step Enrichment of Cells with Multi-locus Knockins through SEED-Selection
One-step Enrichment of Cells with Multi-locus Knockins through SEED-Selection
Crystal Chen, Stanford University
Autonomous T Cell Activation-inducible mRNA Switches for Enhanced Cell Therapy
Autonomous T Cell Activation-inducible mRNA Switches for Enhanced Cell Therapy
Yuxiao Wang, Myeloid Therapeutics
Novel Chimeric Antigen Receptors for In Vivo Programing of Immune Cells to Target Cancer
Novel Chimeric Antigen Receptors for In Vivo Programing of Immune Cells to Target Cancer
Coffee Available
4:30–5:00 PM
Sweeney Ballroom Foyer
Novel Cancer Cell Therapies
5:00–7:00 PM
Sweeney Ballroom A-B
Dan S. Kaufman, University of California, San Diego
Engineered iPSC-Derived Immune Cells for Improved Cancer Therapies
Engineered iPSC-Derived Immune Cells for Improved Cancer Therapies
Katy Rezvani, University of Texas MD Anderson Cancer Center
Clinical Translation of Engineered NK Cell-Based Therapies
Clinical Translation of Engineered NK Cell-Based Therapies
Avery D. Posey, University of Pennsylvania
Novel Targets for CAR-T Cell-Based Therapy
Novel Targets for CAR-T Cell-Based Therapy
Amy N. Courtney, Baylor College of Medicine
Short Talk: Allogeneic NKT Cells Expressing a CD19-specific CAR in Patients with Relapsed or Refractory B Cell Malignancies: An Interim Analysis
Short Talk: Allogeneic NKT Cells Expressing a CD19-specific CAR in Patients with Relapsed or Refractory B Cell Malignancies: An Interim Analysis
Theodoros Giavridis, Mnemo Therapeutics, Inc.
Short Talk: Identification of Novel, Recurrent Tumor-specific Targets for Next-generation Cancer Immunotherapies
Short Talk: Identification of Novel, Recurrent Tumor-specific Targets for Next-generation Cancer Immunotherapies
Social Hour with Lite Bites
7:00–8:00 PM
Sweeney Ballroom F
Poster Session 2
7:30–10:00 PM
Sweeney Ballroom F
Thursday, January 25, 2024
Breakfast
7:00–8:00 AM
Sweeney Ballroom F
Cell Therapy for Infectious Disease and Autoimmune Disease
8:00–11:00 AM
Sweeney Ballroom A-B
Silke Paust, The Jackson Laboratory for Genomic Medicine
Remote Presentation: Mechanisms that Regulate NK Cell Anti-Viral Activity
Remote Presentation: Mechanisms that Regulate NK Cell Anti-Viral Activity
Corina Amor, Cold Spring Harbor Laboratory
Short Talk: Prophylactic and Long-lasting Efficacy of Senolytic CAR T Cells Against Age-related Phenotypes
Short Talk: Prophylactic and Long-lasting Efficacy of Senolytic CAR T Cells Against Age-related Phenotypes
Samik Basu, Cabaletta Bio
CD19 CAR-T Cells for the Treatment of Autoimmune Disease
CD19 CAR-T Cells for the Treatment of Autoimmune Disease
Helen Heslop, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's
Anti-Viral Cell Therapy
Anti-Viral Cell Therapy
Mila Bjelica, CHU Sainte Justine
Short Talk: Developing CAR-NK Cells Against Severe Acute Respiratory Syndrome Coronavirus 2 for Immunocompromised Individuals
Short Talk: Developing CAR-NK Cells Against Severe Acute Respiratory Syndrome Coronavirus 2 for Immunocompromised Individuals
Coffee Break
9:00–9:20 AM
Sweeney Ballroom Foyer
On Own for Lunch
11:00–5:00 PM
Coffee Available
4:30–5:00 PM
Sweeney Ballroom Foyer
HSC and Gene Therapy (Joint)
5:00–6:45 PM
Sweeney Ballroom A-B
Emmanuelle Passegué, Columbia University
Metabolic and Stress Regulation of HSCs
Metabolic and Stress Regulation of HSCs
Raffaella Di Micco, Ospedale San Raffaele
Mechanistic Insights to Advance HSC-Based Gene and Cell Therapies
Mechanistic Insights to Advance HSC-Based Gene and Cell Therapies
Donald B. Kohn, University of California, Los Angeles
HSC Gene Therapy for Immunodeficiencies
HSC Gene Therapy for Immunodeficiencies
Meeting Wrap-Up: Outcomes and Future Directions (Joint) (Organizers)
6:45–7:00 PM
Sweeney Ballroom A-B
Social Hour with Lite Bites
7:00–8:00 PM
Sweeney Ballroom F
Cash Bar
8:00–9:00 PM
Sweeney Ballroom F
Friday, January 26, 2024
Departure
7:00–11:59 PM
Subscribe for Updates